Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,452,301
  • Shares Outstanding, K 165,027
  • Annual Sales, $ 0 K
  • Annual Income, $ -317,420 K
  • EBIT $ -449 M
  • EBITDA $ -451 M
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.23

Options Overview Details

View History
  • Implied Volatility 125.93% (-9.86%)
  • Historical Volatility 70.15%
  • IV Percentile 47%
  • IV Rank 29.54%
  • IV High 253.75% on 10/21/25
  • IV Low 72.33% on 08/18/25
  • Expected Move (DTE 11) 3.03 (17.41%)
  • Put/Call Vol Ratio 1.41
  • Today's Volume 368
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 7,021
  • Open Int (30-Day) 6,005
  • Expected Range 14.35 to 20.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.74
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.78
  • Prior Year -1.05
  • Growth Rate Est. (year over year) +29.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.00 +23.36%
on 03/02/26
17.45 -1.03%
on 02/10/26
+0.28 (+1.65%)
since 02/09/26
3-Month
14.00 +23.36%
on 03/02/26
21.00 -17.76%
on 12/23/25
-1.17 (-6.34%)
since 12/09/25
52-Week
6.36 +171.54%
on 04/09/25
25.00 -30.92%
on 10/28/25
+4.87 (+39.27%)
since 03/07/25

Most Recent Stories

More News
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1  - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen...

DYN : 16.94 (+14.00%)
Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE...

DYN : 16.94 (+14.00%)
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 16.94 (+14.00%)
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 16.94 (+14.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 16.23
2nd Resistance Point 15.79
1st Resistance Point 15.33
Last Price 16.94
1st Support Level 14.43
2nd Support Level 13.99
3rd Support Level 13.53

See More

52-Week High 25.00
Fibonacci 61.8% 17.88
Last Price 16.94
Fibonacci 50% 15.68
Fibonacci 38.2% 13.48
52-Week Low 6.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar